Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Objective：The present trial aimed to assess efficacy and safety of Jin Ling Guan and Tofer infant formula on body growth, intestinal tolerance, gut microbiota and fecal residual nutrients as compared to breast-milk in term Chinese infants.
Participants：189 healthy termed-infants with ages of 5-14 days at the enrollment.
Study Design: A multiple-center, quasi-randomized,open labeled, controlled trial. Random allocation between the two infant formula.
Arms, Groups, and Intervention: (1) Breast milk-fed group: fed with human breast milk; (2) JINLINGGUAN Formula Group：fed with JINLINGGUAN infant formula (PRO-KIDO™ I-PROTECH®, Phase I); (3) TOFER Formula Group: feeding TOFER infant formula (TOFER®, Phase I). Random allocation performed between the two formula groups.
Intervention Duration: 12 weeks.
Visits: 1 week(baseline), 7 and 13 weeks of age
Outcome measures: (1) General information, general health and wellbeing, regular body check;(2) Anthropometric parameters: body length, body weight, and head circumferences; (3) Stool characteristics (color , volume, stool consistency, and frequency;(4)Behavior and habits; (5) Gut microbiota; (6) Residual nutrients in feces (nitrogen,total fat, fatty acids, minerals); (7) adverse events and concomitant medications; (8) compliance. Slopes of changes from baseline to 6 and 12 weeks post intervention in anthropometric parameters, stool characteristic index, fecal residual nutrients, pattern score of gut microbiota, behavior and habit index were be calculated.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Breast-Fed Group | Active Comparator | The infants will be fed with human breast milk by their mother |
|
| TOFER Formula Group | Experimental | TOFER Infant formula,TOFER®: Infants will be fed by using TOFER® infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age. |
|
| JINLINGGUAN Formula Group | Experimental | JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: Infants will be fed by using JINLINGGUAN (PRO-KIDO™ I-PROTECH®) infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH® | Other | JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China |
| Measure | Description | Time Frame |
|---|---|---|
| Average Change Rate of Stool Characteristic Index from Baseline to 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in Stool Characteristic Index: calculated using stool color (using sample pictures), volume (small, normal or large using sample picture scale), stool consistency (runny, mushy, soft, formed or hard), and frequency | 0, 6, 12 weeks |
| Average Change Rate of Fecal Residual Nitrogen from Baseline to 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in Fecal Residual Nitrogen | 0, 6, 12 weeks |
| Average Change Rate of Fecal Residual Fat from Baseline to 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in fecal residual total fat | 0, 6, 12 weeks |
| Average Change Rate of Fecal Residual Calcium from Baseline to 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in fecal residual calcium | 0, 6, 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Average Change Rate of an Index of General health and wellbeing from Baseline to 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in Index of General health and wellbeing, calculated from diseases (cold, diarrhea, bronchitis, pneumonia), doctor visits, gastro symptoms,etc. | 0, 6, 12 weeks |
| Average Change Rate of Behavior and Habit Score from Baseline to 6 and 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Average Change Rate of Fecal Residual Iron from Baseline at 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in fecal residual iron | 0, 6, 12 weeks |
| Average Change Rate of Fecal Residual Zinc from Baseline at 6 and 12 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yuming Chen, Ph.D. | Contact | 8613710230430 | chenyum@mail.sysu.edu.cn | |
| Qian Zhou | Contact | 862087330726 | zhouq83@mail.sysu.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Yuming Chen, Ph.D. | Sun Yat-sen University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lankao Hospital | Terminated | Kaifeng | Henan | China | ||
| Shaoyang Center Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008895 | Milk, Human |
| ID | Term |
|---|---|
| D008892 | Milk |
| D001628 | Beverages |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Researchers involved in laboratory tests will be blinded to the group status
|
| TOFER Infant formula,TOFER® | Other | TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China |
|
| Breast milk | Other | Breast milk: Human breast milk, provided and fed by the corresponding infant's mother |
|
Slope of change at 0, 6 and 12 weeks in Behavior and Habit Score assessed by infant behavior questionnaires |
| 0, 6, 12 weeks |
| Average Change Rate of body length from Baseline to 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in body length | 0, 6, 12 weeks |
| Average Change Rate of Body Weight from Baseline to 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in body weight | 0, 6, 12 weeks |
| Average Change Rate of Head Circumference from Baseline to 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in head circumference | 0, 6, 12 weeks |
| Average Change Rate of Gut Microbiota Pattern Score from Baseline at 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in gut microbiota pattern score from 16S RNA sequencing | 0, 6, 12 weeks |
| Average Change Rate of Pattern Score of Fecal Residual Fatty acids from Baseline at 6 and 12 weeks | Slope of change at 0, 6 and 12 weeks in the pattern score of fecal residual fatty acids | 0, 6, 12 weeks |
Slope of change at 0, 6 and 12 weeks in fecal residual zinc
| 0, 6, 12 weeks |
| Recruiting |
| Shaoyang |
| Hunan |
| China |
|
| Nanxiong Hospital | Terminated | Shaoguan | China |
| D003611 |
| Dairy Products |
| D005502 | Food |
| D019602 | Food and Beverages |